107 related articles for article (PubMed ID: 30447706)
1. Correlations of MicroRNA-21 Gene Polymorphisms With Chemosensitivity and Prognosis of Cervical Cancer.
Zhang J; Li YH; Liu HL; Zhang Y; Zhang QS; Li SZ
Am J Med Sci; 2018 Dec; 356(6):544-551. PubMed ID: 30447706
[TBL] [Abstract][Full Text] [Related]
2. Association study of relationships of polymorphisms in the miR-21, miR-26b, miR-221/222 and miR-126 genes with cervical intraepithelial neoplasia and cervical cancer.
Yang J; Yan Z; Wang Y; Xu J; Li R; Li C; Liu S; Shi L; Yao Y
BMC Cancer; 2021 Sep; 21(1):997. PubMed ID: 34488676
[TBL] [Abstract][Full Text] [Related]
3. iASPP induces EMT and cisplatin resistance in human cervical cancer through miR-20a-FBXL5/BTG3 signaling.
Xiong Y; Sun F; Dong P; Watari H; Yue J; Yu MF; Lan CY; Wang Y; Ma ZB
J Exp Clin Cancer Res; 2017 Apr; 36(1):48. PubMed ID: 28399926
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.
Nishio S; Kitagawa R; Shibata T; Yoshikawa H; Konishi I; Ushijima K; Kamura T
Cancer Chemother Pharmacol; 2016 Oct; 78(4):785-90. PubMed ID: 27553435
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
[TBL] [Abstract][Full Text] [Related]
6. Potential molecular mechanisms for improved prognosis and outcome with neoadjuvant chemotherapy prior to laparoscopical radical hysterectomy for patients with cervical cancer.
Sun H; Xin J; Lu Z; Wang N; Liu N; Guo Q
Cell Physiol Biochem; 2013; 32(5):1528-40. PubMed ID: 24335178
[TBL] [Abstract][Full Text] [Related]
7. Concurrent paclitaxel/cisplatin chemoradiotherapy with or without consolidation chemotherapy in high-risk early-stage cervical cancer patients following radical hysterectomy: preliminary results of a phase III randomized study.
Zhao H; Li L; Su H; Lin B; Zhang X; Xue S; Fei Z; Zhao L; Pan Q; Jin X; Xie C
Oncotarget; 2016 Oct; 7(43):70969-70978. PubMed ID: 27391158
[TBL] [Abstract][Full Text] [Related]
8. Functional variants in TNFAIP8 associated with cervical cancer susceptibility and clinical outcomes.
Shi TY; Cheng X; Yu KD; Sun MH; Shao ZM; Wang MY; Zhu ML; He J; Li QX; Chen XJ; Zhou XY; Wu X; Wei Q
Carcinogenesis; 2013 Apr; 34(4):770-8. PubMed ID: 23299407
[TBL] [Abstract][Full Text] [Related]
9. MiR-1284 enhances sensitivity of cervical cancer cells to cisplatin via downregulating HMGB1.
Chen J; Li G
Biomed Pharmacother; 2018 Nov; 107():997-1003. PubMed ID: 30257412
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.
Kitagawa R; Katsumata N; Shibata T; Kamura T; Kasamatsu T; Nakanishi T; Nishimura S; Ushijima K; Takano M; Satoh T; Yoshikawa H
J Clin Oncol; 2015 Jul; 33(19):2129-35. PubMed ID: 25732161
[TBL] [Abstract][Full Text] [Related]
11. Expression of the lncRNA ZFAS1 in cervical cancer and its correlation with prognosis and chemosensitivity.
Feng LL; Shen FR; Zhou JH; Chen YG
Gene; 2019 May; 696():105-112. PubMed ID: 30738960
[TBL] [Abstract][Full Text] [Related]
12. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine.
Viñolas N; Provencio M; Reguart N; Cardenal F; Alberola V; Sánchez-Torres JM; Barón FJ; Cobo M; Maestu I; Moreno I; Mesía C; Izquierdo A; Felip E; López-Brea M; Márquez A; Sánchez-Ronco M; Tarón M; Santarpia MC; Rosell R;
Lung Cancer; 2011 Feb; 71(2):191-8. PubMed ID: 20627363
[TBL] [Abstract][Full Text] [Related]
13. Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.
Miyata Y; Matsuo T; Nakamura Y; Yasuda T; Ohba K; Takehara K; Sakai H
Anticancer Res; 2018 Mar; 38(3):1629-1635. PubMed ID: 29491095
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study.
Buda A; Fossati R; Colombo N; Fei F; Floriani I; Gueli Alletti D; Katsaros D; Landoni F; Lissoni A; Malzoni C; Sartori E; Scollo P; Torri V; Zola P; Mangioni C
J Clin Oncol; 2005 Jun; 23(18):4137-45. PubMed ID: 15961761
[TBL] [Abstract][Full Text] [Related]
15. Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy.
Braicu EI; Fotopoulou C; Chekerov R; Richter R; Blohmer J; Kümmel S; Stamatian F; Yalcinkaya I; Mentze M; Lichtenegger W; Sehouli J
Cytokine; 2013 Mar; 61(3):755-8. PubMed ID: 23415672
[TBL] [Abstract][Full Text] [Related]
16. Long Noncoding RNA GAS5, Which Acts as a Tumor Suppressor via microRNA 21, Regulates Cisplatin Resistance Expression in Cervical Cancer.
Wen Q; Liu Y; Lyu H; Xu X; Wu Q; Liu N; Yin Q; Li J; Sheng X
Int J Gynecol Cancer; 2017 Jul; 27(6):1096-1108. PubMed ID: 28472815
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
Karageorgopoulou S; Kostakis ID; Gazouli M; Markaki S; Papadimitriou M; Bournakis E; Dimopoulos MA; Papadimitriou CA
BMC Cancer; 2017 Jun; 17(1):451. PubMed ID: 28659181
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant paclitaxel and cisplatin in uterine cervical cancer: long-term results.
Park DC; Suh MJ; Yeo SG
Int J Gynecol Cancer; 2009 Jul; 19(5):943-7. PubMed ID: 19574789
[TBL] [Abstract][Full Text] [Related]
19. A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.
Hong MJ; Lee SY; Choi JE; Jin CC; Kang HJ; Baek SA; Lee SY; Shin KM; Jeong JY; Lee WK; Yoo SS; Lee J; Cha SI; Kim CH; Son JW; Park JY
Oncotarget; 2016 Mar; 7(13):15948-58. PubMed ID: 26893365
[TBL] [Abstract][Full Text] [Related]
20. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients.
Ferrandina G; Lauriola L; Distefano MG; Zannoni GF; Gessi M; Legge F; Maggiano N; Mancuso S; Capelli A; Scambia G; Ranelletti FO
J Clin Oncol; 2002 Feb; 20(4):973-81. PubMed ID: 11844819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
